Posts by Sandra Ansanay-Alex
SDSC and Canton of Vaud Support Bewe Lab and Perivision
Bewe Lab and Perivision are among the four companies selected by Canton de Vaud and the Swiss Data Science Center (SDSC) to join a new programme to help companies boost their projects with artificial intelligence and data science. The goal is to establish artificial intelligence as a key part of the Vaud economy. Bewe Lab:…
Read MoreImmitra Bio Receives a CHF 150,000 Gebert Rüf Stiftung InnoBooster Grant
Geneva-based startup Immitra Bio has been selected as one of the latest winners of the InnoBooster programme, supported by the Gebert Rüf Stiftung. This CHF 150,000 grant will be used to build a scalable in-vivo gene-editing platform to make genetic therapies accessible to all patients, regardless of where they live or their financial means. Founded…
Read MoreHAS Healthcare Advanced Synthesis Group Announces Strategic Investments in Biodelphis Therapeutics
HAS Healthcare Advanced Synthesis (Ticino) and Biodelphis Therapeutics (Vaud) announced the signing of a strategic agreement to support the development and GMP manufacturing of Antibody Protease Inhibitor Conjugates, an emerging class of targeted therapeutics designed to selectively inhibit disease‑driving proteases. This collaboration combines HAS Group long‑standing expertise in complex bioconjugation, process development, and clinical‑grade manufacturing…
Read MoreMoonlight AI AG Raises $3.3M Seed Round
Moonlight AI AG, a Swiss startup building image analysis software for clinical-grade diagnostics, has closed a $3.3 million USD Seed round. The investment was co-led by Lotus One Investment (Singapore), VP Venture Partners (Switzerland), and MEDIN Fund (Tunisia), with participation from N&V Capital (Liechtenstein) and existing investor QAI Ventures (Switzerland). Turning routine slide images into…
Read MoreSwiss Biotech on the Rise: Strong Momentum in 2025
Switzerland’s biotech sector continues to demonstrate remarkable resilience and growth, even in a complex global environment. According to the latest Swiss Biotech Report 2026, the industry reached new heights in 2025—both in terms of revenue and investment—further strengthening the country’s position as a global life sciences powerhouse. Record performance in a challenging context The numbers…
Read MoreSantExpo
SantExpo, one of France’s largest gathering dedicated to healthcare, is taking place from 25 to 27 May 2027 in Paris. SantExpo is the premier event for healthcare decision-makers and professionals: in 2026, it brought together 35,150 attendees, 695 exhibitors, and 530 speakers to discuss the sector’s strategic challenges. The theme for 2026 is “excellence in…
Read MoreCHUV Acquires a Single-Incision Surgical Robot
Up to 400 patients per year could benefit from the “Da Vinci Single Port” system, developed by Intuitive Surgical, which is designed to minimize tissue damage—and thus speed up recovery time. The University Hospital of Lausanne (CHUV) announces the launch of a single-port surgical robot—a first in French-speaking Switzerland, according to the institution. The “Da…
Read MoreTwo Research Teams from HUG and UNIGE Awarded the 2026 Leenaards Scientific Prize
Two research groups from Hôpitaux Universitaires de Genève (HUG) and Université de Genève (UNIGE) have been awarded the 2026 Leenaards Foundation Scientific Prize, with total funding of nearly CHF 1.4 million. The award supports two biomedical research projects conducted in the Lake Geneva region, focusing respectively on hepatitis E and an innovative, non-invasive approach to…
Read MoreMedtronic Reaches 10 Million Implantable Devices Produced in Switzerland
In Switzerland, precision and innovation are more than values—they are an industrial signature. Few companies embody that better than Medtronic, which is celebrating a dual milestone: 50 years of presence in the country and the production of its 10 millionth implantable device at its Tolochenaz (Canton of Vaud) site. A Swiss industrial success story Medtronics…
Read MoreMindMaze Therapeutics Narrows Losses and Prepares for Commercial Takeoff in 2026
MindMaze Therapeutics’ 2025 Annual Report tells a story of transition—one where financial discipline begins to align with long-term commercial ambition. The Swiss-based neurotechnology company gears up for a broader market launch in 2026. Mindmaze reported CHF 0.6 million in revenue for 2025, alongside operating expenses of CHF 11.2 million and a net loss of CHF…
Read More